摘要
目的观察胰升血糖素样肽-1(GLP-1)受体激动剂和二肽基肽酶-4(DPP-4)抑制剂对于治疗T2DM的临床疗效。方法将T2DM患者按随机数字表法分为DPP-4组和GLP-1组,每组各40例。26周后,观察两组治疗疗效及各项指标的变化。结果 26周后,两组FPG及HbA1c均较治疗前下降(P<0.05),与DPP-4组比较,GLP-1组下降更明显。结论 GLP-1治疗T2DM的疗效优于DPP-4,值得在临床上推广使用。
Objective To observe the clinical effects of glucagon-like peptide-1 （GLP-1） receptor agonist versus sitagliptin dipeptidyl peptidase-4 （DPP-4） inhibitor for the treatment of type 2 diabetes mellitus （T2DM）.Methods Patients with type 2 diabetes were divided into the DPP-4 group （n=40） and GLP-1 group（n =40） according to random digits table.After 26 weeks,the curative effects and changes of each indicator in the two groups were observed.Results After 26 weeks of treatment,the FPG and HbA1 c of two groups were decreased as compared with those before treatment （P＜0.05）.And the HbA1c decrement of GLP-1 group is better than that of DPP-4 group（P＜0.05）.Conclusion The curative effect of GLP-1 is better than that of DPP-4 in the treatment of type 2 diabetes,thus GLP-1 is worth of popularizing in clinical use.
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2014年第8期731-733,共3页
Chinese Journal of Diabetes
关键词
糖尿病
2型
二肽基肽酶-4
胰升血糖素样肽-1
Diabetes mellitus, type 2
Dipeptidyl peptidase-4 （DPP-4）
Glucagon-like peptide-1 （GLP-1）
